Understanding Immune Cells in Cancer Treatment
Regulatory T cells in cancer therapy
This research explores how certain immune cells, called regulatory T cells, behave in the unique environment of a tumor and affect the body's ability to fight cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11117191 on NIH RePORTER |
What this research studies
Our bodies have special immune cells called regulatory T cells, or Tregs, that normally help keep our immune system balanced. However, in cancer, these Tregs can gather around tumors and prevent other immune cells from attacking the cancer effectively. This project aims to understand how the unique metabolic environment within a tumor affects these Tregs. By learning how Tregs behave and are influenced by the tumor's metabolism, we hope to find new ways to make cancer treatments, like immunotherapy, more powerful.
Who could benefit from this research
Good fit: Patients with various types of cancer, particularly those who might benefit from or are undergoing immunotherapy, are the ultimate focus of this foundational research.
Not a fit: Patients whose cancer does not involve significant immune suppression by regulatory T cells or who are not candidates for immunotherapy may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to new strategies to enhance the effectiveness of cancer immunotherapies by overcoming immune suppression within tumors.
How similar studies have performed: While the general role of regulatory T cells in cancer is known, this project explores a new aspect of how their metabolism within tumors affects their function.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Zou, Weiping — University of Michigan at Ann Arbor
- Study coordinator: Zou, Weiping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.